CN105367511A - Pharmaceutical composition used for treating bone diseases - Google Patents
Pharmaceutical composition used for treating bone diseases Download PDFInfo
- Publication number
- CN105367511A CN105367511A CN201510902274.4A CN201510902274A CN105367511A CN 105367511 A CN105367511 A CN 105367511A CN 201510902274 A CN201510902274 A CN 201510902274A CN 105367511 A CN105367511 A CN 105367511A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- compound
- osteopathy
- treatment
- bone diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a pharmaceutical composition used for treating bone diseases. The pharmaceutical composition comprises an effective dose of a compound, and a pharmaceutically acceptable carrier; and the structure of the compound is represented by a formula in the invention. The compound possesses excellent effect in treating bone diseases, and continuous development and research of the compound into a novel pharmaceutical composition effective in clinical application is promising.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to a kind of pharmaceutical composition for the treatment of osteopathy.
Background technology
Osteopathy generally comprises: rheumatic arthritis, rheumatoid arthritis, degenerative osteoarthritis, ankylosing spondylitis, cervical spondylosis, lumbar spondylosis, scapulohumeral periarthritis, hyperosteogeny, necrosis of femoral head, puerperal exposure to wind etc.Rheumatic arthritis (rheumatoidarthritis) is a kind of common acute or chronic ICT.Can recurrent exerbation involve heart.Clinical with joint and muscle migrans miserable, heavily work, pain for feature, belong to allergic disorder, be one of main manifestations of rheumatic fever, mainly with febris acuta and arthralgia onset.The chronic generalized autoimmune disorder of rheumatoid arthritis (rheumatoidarthritis) to be a kind of with arthrosynovitis be feature.The lasting recurrent exerbation of synovitis, can cause the destruction of intraarticular cartilage and bone, joint function disturbance, even maimed.Vasculitis pathology involves each organ of whole body, therefore this disease is also called similar rheumatism.Necrosis of femoral head, also known as ischemic necrosis of the femoral head, is one of common osteoarthropathy.Mostly because the illness such as rheumatosis, hemopathy, submarine sickness, burn cause, first destroy the blood supply of adjacent joints covering weave, and then cause necrosis.Its cardinal symptom, develops into rest pain gradually from discontinuity pain, then cause muscle spasm by pain, joint motion is restricted, finally cause and seriously disable and walk lamely.Hormone drug also can cause the generation of this disease.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of osteopathy.
In order to realize object of the present invention, the invention provides a kind of compound for the treatment of osteopathy, this compound has having structure:
The present invention also provides a kind of pharmaceutical composition for the treatment of osteopathy, and described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
Preferably, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
Preferably, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
Preferably, described thinner is lactose.
Preferably, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
The present invention also provides the purposes of compound in the medicine of preparation treatment osteopathy, and this compound has having structure:
Term used herein " pharmaceutically acceptable " refers to not eliminate the biologic activity of compound as herein described or the material of character, as carrier or thinner.This kind of material is applied to and individual does not cause undesirable biological action or not with harmful way and any component interaction comprised in its composition.
" pharmaceutically acceptable carrier " comprises any and all solvents as the term is employed herein, dispersion medium, coating material, tensio-active agent, antioxidant, sanitas (such as antiseptic-germicide, anti-mycotic agent), isotonic agent, absorption delay agent, salt, sanitas, drug stabilizing agent, tackiness agent, vehicle, disintegrating agent, lubricant, sweeting agent, correctives, dyestuff etc. and its combination, this is well-known to those skilled in the art (for example, see Remington'sPharmaceuticalSciences, 18thEd.MackPrintingCompany, 1990, pp.1289-1329).Except with except the inconsistent carrier of activeconstituents, consider to use any conventional carrier in treatment or pharmaceutical composition.
Compound of the present invention, for the pathogenic bacteria Be very effective causing stomach and intestine, can be developed to pharmaceutical composition effectively new clinically.
Embodiment
Below by way of the description of embodiment, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
Experimental example
The structural formula of target compound is:
Osteoarthritis is the coefficient result of mechanics and biological factor, thinks that IgG1 raises at present relevant with the severity of the course of disease and disease.Therefore can by judging that the level of IgG1 evaluates the effect of medicine.
Knee osteoarthritis model and administration
By cleaning grade (SPF) male Wistar rat (mouse 5-6 in the age month, weight 170.0 ± 20.5) be divided into 4 groups: Normal group (Normalcontrolgroup, NC), model control group (Modelcontrolgroup, MC), glucosamine control group (Glucosaminecontrolgroup, GS), administration group.Often organize 10.Except Normal group, respectively organize the Cys aqueous solution of right knee joint injection 4 % by weight Papain enzyme aqueous solution 10 μ L and 0.03mol/L of rat to all the other, and strengthened respectively at the 3rd, 7 day, cause osteoarthritis.After modeling the 14th day starts administration, and each group dosage is as follows: normal group and model group, give physiological saline gavage 1mL/100g body weight; Glucosamine group, glucosamine 1g adds 100mL normal saline and becomes suspension, gives gavage 1mL/100g body weight; Administration group, the target compound of 0.01g adds 1000mL normal saline and becomes suspension, gives gavage 1mL/100g body weight.1 times/day, successive administration 30d, draws materials for after modeling the 49th day.
ELISA method detects IgG1
The 49th day by sacrifice of animal after, row aorta abdominalis take a blood sample, by the centrifugal 5min of institute blood sampling 3000r/min, get serum, put-80 DEG C of Refrigerator stores to be measured.Concrete operation step is undertaken by test kit (IgG1ELISA test kit is purchased from Mei Lian bio tech ltd, Shanghai) specification sheets.The results are shown in following table.
| Group | IgG1(μg·mL -1) |
| Normal group | 107.42±9.13 |
| Model group | 151.22±10.55 |
| Glucosamine group | 132.34±8.62 |
| Administration group | 113.38±7.18 |
Claims (7)
1. treat a compound for osteopathy, it is characterized in that, this compound has having structure:
2. treat a pharmaceutical composition for osteopathy, it is characterized in that, described pharmaceutical composition includes the compound of effective amount and pharmaceutically acceptable carrier, and described compound has having structure:
3. the pharmaceutical composition for the treatment of osteopathy according to claim 2, is characterized in that, described pharmaceutically acceptable carrier is thinner, disintegrating agent, tackiness agent, lubricant, stablizer or corrigent.
4. the pharmaceutical composition for the treatment of osteopathy according to claim 3, is characterized in that, described thinner is sugar derivatives, starch derivative or derivatived cellulose.
5. the pharmaceutical composition for the treatment of osteopathy according to claim 4, is characterized in that, described thinner is lactose.
6. the pharmaceutical composition for the treatment of osteopathy according to claim 3, is characterized in that, described pharmaceutical composition is powder, microgranules, granule, capsule or tablet.
7. the purposes of compound in the medicine of preparation treatment osteopathy, it is characterized in that, this compound has having structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902274.4A CN105367511A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition used for treating bone diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510902274.4A CN105367511A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition used for treating bone diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105367511A true CN105367511A (en) | 2016-03-02 |
Family
ID=55370199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510902274.4A Pending CN105367511A (en) | 2015-12-08 | 2015-12-08 | Pharmaceutical composition used for treating bone diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105367511A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305997A (en) * | 2001-01-08 | 2001-08-01 | 中国药科大学 | Diclofenac coupled derivative and its synthesizing process and inflammation relieving action |
-
2015
- 2015-12-08 CN CN201510902274.4A patent/CN105367511A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305997A (en) * | 2001-01-08 | 2001-08-01 | 中国药科大学 | Diclofenac coupled derivative and its synthesizing process and inflammation relieving action |
Non-Patent Citations (3)
| Title |
|---|
| WEIBIN TANG 等.: "Novel Nitric Oxide-Releasing Derivatives of Brusatol as Anti-Inflammatory Agents: Design, Synthesis, Biological Evaluation, and Nitric Oxide Release Studies", 《J. MED. CHEM.》 * |
| 李瑞文 等: "苯基呋咱氮氧化物与双氯芬酸偶联化合物的合成及其抗炎镇痛活性", 《药学学报》 * |
| 百度百科: "诺贝康一氧化氮", 《网络公开》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Punzi et al. | Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets | |
| EP2708147B1 (en) | Methods for increasing brain functionality using 2-fucosyl-lactose | |
| CN105125610B (en) | Sunflower disk hydrolyzes application of the compound powder in preparing treatment or alleviating high lithemia gout disease drug | |
| Voulgari et al. | Infliximab therapy in established rheumatoid arthritis: an observational study | |
| CN102026641A (en) | Pharmaceutical preparation comprising DPP-IV inhibitor and other diabetes therapeutic agent in concomitant or combined form | |
| JPH0223526B2 (en) | ||
| EA025365B1 (en) | Use of cd37 antibody for treating a patient belonging to a high risk group, suffering from chronic lymphocytic leukemia (cll), method of depleting cd37 expressing b cells from a population of tp53 deficient cells | |
| KR100290132B1 (en) | Pyrimidine nucleotide precursors for systemic inflammation and inflammatory hepatitis | |
| ES2699722B1 (en) | COMPOSITION TO TREAT DISEASES OF MOTOR NEURONS AND USE OF THE SAME | |
| CN105263579A (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| Gudbrandsdottir et al. | Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children. | |
| Kokot et al. | Hepatic inactivation of renin in man | |
| CN105367511A (en) | Pharmaceutical composition used for treating bone diseases | |
| CN105770870A (en) | Enzyme-contained natural composition and application thereof in pharmacy | |
| Zhang et al. | The ACE2 activator diminazene aceturate ameliorates colitis by repairing the gut-vascular barrier in mice | |
| CN105348171A (en) | Pharmaceutical composition for treating knee osteoarthritis | |
| CN105294533A (en) | Pharmaceutical composition for treating bone diseases | |
| CN110038114A (en) | A kind of purposes of polypeptide in preparation prevention or treatment metabolic syndrome drug | |
| CN106727584A (en) | A kind of pharmaceutical composition for treating osteopathy | |
| Boccagni et al. | Churg-Strauss syndrome associated with the leukotriene antagonist montelukast | |
| CN105395553A (en) | Pharmaceutical composition for osteoarticular disease rehabilitation | |
| WO2015084706A1 (en) | Intra-articular formulations and methods for treatment of osteoarthritis | |
| Zhu et al. | Effects of individual shock wave therapy vs celecoxib on hip pain caused by femoral head necrosis | |
| CN103933277A (en) | Tibetan drug for treating gout disease | |
| CN105541838A (en) | Medicine composition for treating kidney stones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160302 |